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Abstract  
Purpose: To assess the effect of “N-Acetylation and C-Amidation” on the cellular uptake, cytotoxicity and 
performance of amphiphilic Cell Penetrating Peptides loaded with MTX. 
Methods: Several CPPs were synthesized by solid phase peptide synthesis method. Some of these sequences 
were modified with Pyroglutamic acid at N-terminus and Benzylamine or memantine at C-terminus. The 
resultant nanomaterials were prepared due to the physical linkage between CPPs and methotrexate (MTX). 
The Internalization and cytotoxicity of both CPP-MTX bioconjugates and unmodified CPPs against MCF-
7 cells was evaluated.  
Results: N-terminal and C-terminal modification did not alter the toxicity of CPPs. Physical linkage of CPPs 
with MTX resulted in a lower drug loading efficiency in comparison with chemically conjugated CPP-
MTX bioconjugates. Both nanoparticles increase the toxic effect of MTX on MCF-7 cells. Furthermore, N-
terminal and C-terminal modification may cause a tangible reduction in cellular uptake of CPPs. 
Conclusion: In conclusion, it was shown that cytotoxicity of modified peptides which were physically linked 
with MTX, considerably higher than both physically loaded unmodified peptides and chemically 
conjugated peptides with MTX. Also, cell internalization was reduced after peptide end-protection. These 
findings confirmed the effectiveness of N-terminal and C-terminal modifications on cell viability and CPPs 
internalization. 
 
Keywords: Cell Penetrating Peptides, end-capping, Drug loading, Methotrexate, Cellular uptake, Peptide 
nano-complex 
 
 
List of Abbreviations 
 
BA: Benzylamine  
CLSM: Confocal Laser Scanning Microscope 
CPPs: Cell Penetrating Peptides 
CTC Resin: 2-Chlorotrityl Chloride Resin 
DCM: Dichloromethane 
DHFR: Dihydrofolate Reductase 
DIPEA: N, N-diisopropylethylamine 
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DLS: Dynamic Light Scattering 
DMSO: Dimethylsulfoxide 
DMF: N, N –Dimethylformamide 
Et2O: Diethyl ether 
EDTA: Ethylenediaminetetraacetic acid 
FACS: Fluorescence Activated Cells Sorting 
FAM: 5(6) Carboxyfluorescein 
FBS: Fetal Bovine Serum 
Fmoc: 9-fluorenylmethyloxycarbonyl 
FPGS: Folylpolyglutamate synthase 
HIV: Human Immunodeficiency Virus 
HOBt: 1-Hydroxybenzotriazole 
MeOH: Methanol 
Mem: Memantine 
MTBE: Methyl tertiary-butyl ether 
MTT: 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
MTX: Methotrexate 
NMR: Nuclear Magnetic Resonance 
ON: Oligonucleotide 
pAntp: Homeodomain of the Antennapedia Protein 
PBS: Phosphate Buffered Saline 
pGlu: Pyroglutamic Acid 
PNA: Peptide Nucleic Acid 
PTD: Protein Transduction Domain 
PTFE:  Poly-tetrafluoroethylene 
RFC1: Replication Factor C Subunit 1 
SCO: Splice Correcting Oligonucleotides 
SEM: Scanning Electron Microscope 
siRNA: small interfering RNA 
SPPS: Solid Phase Peptide Synthesis 
TAT: Trans-acting Activator of Transcription 
TBTU: N, N, N', N'-Tetramethyl-O-(benzotriazole-l-yl) Uronium Tetrafluoroborate 
TEA: Triethylamine 
TFA: Trifluoroacetic Acid 
TIS: Triisopropylsylane 
ZS: Zetasizer 
 
Background  
A successful drug delivery toward cancer possesses some promising breakthroughs due to its potential 
importance and impacts on human life. Thus, the appealing prospect of newly proposed strategies has made 
the delivery of desired molecules, in the range of small molecules to larger ones, despite their different 
hydrophilicity, as an interesting issue (1). Nowadays, hindrance by the lipid bilayer of the cell membrane 
is considered as a major hurdle in an efficient drug delivery (2). Nanotechnology seeks the most applicable 
approaches in order to overcome some of the restrictions in the scope of drug delivery. To date, one of the 
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most well-known vehicles to circumvent natural cellular barriers (i.e., cellular membrane) is a type of 
peptides called; Cell Penetrating Peptide (CPP) (1, 3-5). CPPs are a kind of peptide sequences composed 
of 5-30 amino acid residues with hydrophobic, cationic or amphiphilic properties (6, 7). These peptides 
have been shown the especial ability to pass through biological membranes spontaneously by energy-
dependent or energy-independent mechanisms and become promising vectors to facilitate the transport of 
biological cargoes (e.g., plasmid DNA, drug molecules, peptide-nucleic-acids (PNAs), oligonucleotides 
(ONs), contrast agents in MRI, siRNA in gene silencing, therapeutic peptides and proteins, nanoparticles, 
etc.) to the cells, both in-vitro and in-vivo (3, 6, 8). As same as other groups of peptides, CPPs are vulnerable 
to be degraded via proteolytic enzymes which are seen in the cells, liver and the blood (9). In order to 
protect these versatile carriers, a wide variety of options have been developed in the recent years (10, 11). 
One of the most common and reliable procedures to stabilize nearly all kinds of peptides is called “N-
Acetylation and C-Amidation". In this method, a compound is attached to the amino terminus of a peptide 
and another compound is coupled to the carboxy terminus of the same peptide. Therefore, a chemical 
modification is applied against exo-peptidases (12, 13). It is noteworthy to consider that a peptide without 
any modification may exhibit immunogenicity or toxic effects. However, peptides with modifications result 
in, whether toxic effects or not. 
Currently, the ideas about how different classes of CPPs enter the cells is still a controversial issue. A 
wide variety of residues can however found in the literature for CPPs. The most prevalent amino acid 
residues, which show extraordinary uptake patterns, are cationic residues (e.g., Arginine (R), Lysine (K)) 
besides tryptophan (W), whereas other residues do not exhibit more remarkable impacts on internalization 
(14, 15). Most of the previous works were focused on TAT (trans-acting activator of transcription; a peptide 
derived from the HIV-1 transactivator protein) and pAntp (homeodomain of the Antennapedia protein) (16, 
17). A very common type of CPPs is polyarginine with different number of residues (e.g., hexa-arginine, 
octa-arginine, nona-arginine, etc.) (18-20). Arginine-rich peptides with few residues could enter the cells 
sufficiently, but the presence of at least eight positive charges is proposed for an efficient cellular 
internalization of cationic or amphiphilic CPPs (21). 
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Methotrexate (MTX) is a chemotherapy agent and immune system suppressant which acts as an 
antagonist of Folate. This drug competitively inhibits dihydrofolate reductase (DHFR) and finally affects 
the production of thymidine monophosphate, which is essential for DNA and RNA synthesis (22). 
Antimetabolites, such as methotrexate, kill proliferating cells only during a specific part(s) of the cell cycle 
(e.g., S-phase; cytotoxic effects primarily occur during this phase of the cell cycle) (23). It is a sophisticated 
mission to prove how N-terminal and C-terminal modification affect cytotoxicity and cellular uptake of 
synthesized CPPs. Aiming to consolidate this research process, loading MTX on desired CPP sequences 
due to delivery to MCF-7 breast adenocarcinoma cancer cells was carried out in two different patterns; the 
physical linkage between drug molecules and desired peptides (modified or unmodified sequences), also 
chemical conjugation of drug molecules to CPPs. Finally, cell viability and cytotoxicity of blank carriers 
(e.g., peptide alone), cell viability and cytotoxicity of drug loaded CPPs; both physically linked and 
chemically conjugated sequences were assessed by MTT assay. In the uptake studies, three groups of 
peptides were chosen and uptake studies were carried out by flow cytometry, fluorescent microscopy, live 
cell imager and CLSM (24).  
The peptides undergo Proteolytic Degradation in the body. It has been shown that N-terminal and/or C-
terminal modification would increase the biological half-life of peptides. This study was conducted to 
investigate the effect of N as well as C terminal modification on the cellular uptake, cytotoxicity and 
performance of amphiphilic Cell Penetrating Peptides loaded with MTX.  
 
Materials and Method 
Materials 
N, N, N', N'-Tetramethyl-O-(benzotriazole-l-yl) Uronium Tetrafluoroborate (TBTU), Triisopropylsylane 
(TIS), 1-hydroxybenztriazole (HOBt), 5(6) Carboxyfluorescein (FAM), Potassium cyanide (KCN), 
Methotrexate (MTX), Propidium Iodide (P. I.), Ninhydrine and Trypsin were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). 3-(4, 5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) was from 
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Roth (Karlsruhe, Germany). Pyridine was obtained from BDH Laboratory Supplies (England). 
Trifluoroacetic acid (TFA) and Piperidine were from Fluka (Buchs, Switzerland). N-ethyldiisopropylamine 
(DIPEA), Triethylamine (TEA), Dimethyl Sulfoxide (DMSO), Methanol (MeOH), Acetic Acid (AcOH), 
Isopropanol, EDTA, Formaldehyde, Paraformaldehyde, Phenol and n-butanol were purchased from Merck 
(Darmstadt, Germany). Diethyl ether (Et2O), methyl tertiary butyl ether (MTBE), dichloromethane (DCM) 
and N, N-dimethylformamide (DMF) were from Scharlau Chemie (Barcelona, Spain), CALEDON 
(Canada) and DAEJUNG (South Korea). Fmoc-amino acid derivatives and 2-Chlorotrityl Chloride Resin 
(loading: 1.08 mmol.g−1) were from AAPPTec (Louisville, KY, USA). Dulbecco’s RPMI-1640 medium 
and Fetal Bovine Serum (FBS) were purchased from Gibco (Grand Island, NY, USA), 
Penicillin/Streptomycin solution was from Applichem (Darmstadt, Germany) and Trypan Blue was 
obtained from Biosera (UK). RNase (DNase-Free) enzyme was purchased from Thermo-Fisher/Invitrogen 
(Massachusetts, USA). Cell Culture T-75 Flask and Cell Culture 96-well and 6-well plates were from Biofil 
(Canada) or SORFA (China). MCF-7 Cell line was obtained from Pasteur Institute (Tehran, Iran). 
 
CPP synthesis 
All Peptides were synthesized manually by SPPS method on 2-Chlorotrityl chloride resin by 9-
fluorenylmethoxycarbonyl chloride (Fmoc) strategy using innovative syringes equipped with PTFE filters 
(25-27). After loading the first amino acid, the desired peptide sequence was assembled in a linear model 
from the C-terminus to the N-terminus (the CN strategy) by repetitive cycles of Nα deprotection and 
amino acid coupling reactions. The Fmoc protected amino acids with different side chain protecting groups 
were used as the following derivatives: Fmoc-Arg (Pbf)-OH, Fmoc-Trp (Boc)-OH, Fmoc-Lys (Boc)-OH, 
Fmoc-Gly-OH, Fmoc-Gln (Trt)-OH and Fmoc-Glu (OtBu)-OH. CPPs were synthesized by adding 250 mg 
of 2-Chlorotrityl chloride resin (loading: 1.08 mmol.g−1) into a 60 ml polypropylene syringe equipped with 
PTFE filter, a Teflon stopcock and stopper. The resin was swollen in dry DCM (approximately 10 ml per 
gram of resin) for 1.5 hrs under dry nitrogen. After removal of the DCM, the first Fmoc-protected amino 
acid coupling was carried out by adding 5.0 equivalents of DIPEA as activating reagent to 2.0 equivalents 
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amino acid in DCM/DMF mixture (3:1). The first amino acid was loaded on the resin at C-terminal and the 
reaction vessel was stirred for three hours. The resin was end-capped by adding 0.8 ml of MeOH for 1 g of 
the resin (0.2 ml for 250 mg), then washed with DCM (2×3 ml) and DMF (2×3 ml). The Fmoc protecting 
group was removed with 2 ml of 20-40% (v/v) Piperidine/anhydrous DMF solution for about 1 hr. The 
resin was then washed with DCM (2×3 ml) and DMF (2×3 ml), respectively. The effectiveness of the 
deprotection was monitored by testing for free amine groups with the Ninhydrin Test. In the next step, 2.0 
equivalents of the Fmoc-protected amino acid and 5.0 equivalents of TBTU as coupling reagent with 5.0 
equivalents of HOBt in 10 ml of DMF were added to the resin. DIPEA (5.0 equivalents) were added and 
the reaction vessels stirred for about three hours at room temperature as the first amino acid coupling. After 
loading the first amino acid, the desired peptide sequence is assembled in a linear fashion from the C-
terminus to the N-terminus by repetitive cycles of Nα deprotection, amino acid coupling reactions and 
washings. Stirring of the reaction mixture at any given step described in this paper was performed by 
attaching the closed polypropylene syringe to a rotating axis. Peptide derivatives were cleaved and 
deprotected by adding 10 ml of cleavage cocktail (TFA/H2O/Phenol/TIS: 88/5/5/2 v/v/v/v). The reaction 
vessel was stirred for about three hours, then the volume was reduced to one-third of the initial volume by 
N2 sparge. The crude peptides were precipitated by cold MTBE and an excess amount of ice-cold diethyl 
ether (10× cleavage cocktail volume) under vigorous stirring. The resulting precipitate containing the 
cleavage cocktail and Et2O/MTBE was harvested by centrifugation (4,000 rpm for five minutes at room 
temperature) and washed more times with diethyl ether. Afterwards, the supernatant was decanted and the 
resulting solid was dried utilizing rotary-evaporator under neutral Argon gas in order to obtain the solid 
peptide precipitate. Afterwards, these solid precipitated peptides were lyophilized by freeze dryer. 
 
Preparation of CPP/E8 Nano-complexes 
CPP/polyglutamate Nano-complexes were prepared at N:P ratios (the molar ratio of positively charged 
amino acids (e.g., Lysine (K) and Arginine (R)) in the peptide to negatively charged amino acids (e.g., 
Glutamic acid (E) in the synthesized polyglutamate sequence)) ranging from 1 to 10 by adding appropriate 
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volumes of peptide solution to 200 µg Poly E (E8). Optimized ratio (1:5) was chosen and peptide nano-
complexes were prepared. The complexes were incubated at room temperature for at least 10 min to allow 
the formation of the nano-complexes. 
 
Modification of CPPs 
An old well-known method to modify a peptide sequence or protein motif is N-terminal and C-terminal 
modification to fulfil some ideas like resistance against exo-peptidases cleavage. N-terminal modification 
of a group of peptides was done with 5(6) Carboxyfluorescein in the case of uptake studies. On the other 
hand, Pyroglutamic acid was chosen to N-terminal modification of another group of peptides to use in 
cytotoxicity and cell viability assays. 5(6) Carboxyfluorescein (FAM) was used as a common fluorescence 
labeling reagent. It is available as a mixture of 5-FAM and 6-FAM isomers (5(6)-FAM). The amino 
protecting groups were removed by Piperidine/DMF 20-40% Solution (2 ml). The resin was washed with 
DMF, then rinsed with DCM (3×2 ml) to remove DMF and dried by a vacuum pump. The desired amount 
of peptide-resin (50 mg) was weighed and poured into a reaction vessel. In a separate vessel, FAM was 
dissolved in DMF to slurry the resin. Then, TBTU and DIPEA were added and mixed gently. The solution 
was added to the resin and vessel was stirred three hours at room temperature. A Kaiser test was performed 
to confirm end point. The resin was washed with DMF (3×4 ml), isopropanol (3×4 ml) and DCM (3×4 ml). 
On the other hand, Pyroglutamic acid (pyrrolidone carboxylic acid; pGlu) was found as the N-terminal 
amino acid in various proteins and polypeptides. N-terminal modification with Pyroglutamic acid (pGlu) 
in cytotoxicity and cell viability assays was performed. The coupling procedure was as same as FAM 
labeling procedure. On the other hand, the C-terminal modification was done by applying Memantine in 
sequences which were used in uptake studies, also Benzylamine was used in cytotoxicity and cell viability 
assays. CTC resin can be used for the preparation of both protected and unprotected peptides. Based on the 
dried amount of peptide-resin (e.g., 50 mg), the produced N-acetylated peptides were cleaved from the resin 
by treatmenting TFA in DCM (1-2%) with the final volume about 5 ml and each peptide’s reaction vessel 
was stirred two hours at room temperature. Neutralization process was performed by the calculated amount 
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of excess DIPEA, then C-amidation of the synthesized peptides was carried out using Memantine (or 
Benzylamine) and HOBt in the presence of TBTU as a coupling reagent, DIPEA as the base and DMF/DCM 
mixture as solvent at room temperature. The mixture in a three-neck glass flask was stirred by a magnetic 
stirrer overnight under vacuum. 
 
Nuclear Magnetic Resonance (NMR) Studies 
To ensure that amidation was carried out, 1H NMR (500.13 MHz) spectra was recorded on a Bruker 
spectrometer (Bruker, Ettlingen, Germany) at 500 MHz using TMS as internal standard and DMSO/D2O 
as a solvent. For the NMR measurements, 5-10 mg of Mem-[WK]4-FAM and BA-QGR-[WR]3-pGlu 
sequences were dissolved in 1 ml of DMSO/D2O solution and experiments were carried out at 298 
◦K.  
 
Dynamic Light Scattering (DLS) and ζ-potential studies 
The hydrodynamic mean diameter and ζ-potential of the modified/unmodified CPPs and their nano-
complexes were determined by Dynamic Light Scattering (DLS) studies. DLS experiments were carried 
out on a Zetasizer Nano ZS apparatus (Malvern Instruments, Malvern, UK). Measurements were performed 
in a disposable 1.0 cm-path length acryl cuvette at 25 °C. Peptides were dissolved in DMSO then 
polyglutamate was added in 1:5 ratio (E8 : CPP) to form Nano-conjugates. CPPs and their nano-complexes 
(i.e., CPP/E8) were diluted to 1 ml with distilled water before the particle size and zeta potential 
measurements (Size measurements were done at least 5 measurements per peptide. In the ζ-potential 
studies, measurements were performed in 15 measurements per sample). 
 
Scanning Electron Microscopy (SEM) 
One day prior to the examination, samples were prepared by drop casting a 5 mM aqueous solution 
(20 μl) of peptides/Nano-complexes dissolved in DMSO onto the Aluminum foils. Samples were dried in 
air at room temperature, then they lyophilized to ensure complete drying, also sputtered with an extra-thin 
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layer of gold in high vacuum mode and finally analyzed by Scanning Electron Microscopy (SEM, Mira3 
FEG-SEM Tescan 5.0 kV) to study the surface morphology and sizes of peptides/Nano-complexes. 
 
Preparation of MTX-Peptide Conjugates 
As a crucial step in this research, peptide-MTX conjugates were prepared by two different procedures 
in order to compare their efficacy and eligibility. There were two options for peptide-drug complex 
preparation. The first one was the chemical conjugation of MTX to some peptide sequences in particular 
circumstances and another option was a physical linkage of CPPs with MTX. However this kind of 
interaction had its limitations like weak attraction force and early release before targeting, it was considered 
expedient due to its ability to interact with more than one drug molecule due to the presence of some cationic 
residues in peptides’ structure (e.g., Arg and Lys).  In the chemical conjugation procedure, Fmoc-protecting 
groups were removed using the standard Fmoc deprotection procedure. The required amount of peptide-
resin was taken and washed with DCM to remove any remaining DMF (3×2 ml), then dried by a vacuum 
pump under argon flow. According to this approach, conjugation of drug to synthesized peptides was 
carried out using Methotrexate in the presence of TBTU, DIPEA and DMF at room temperature. The 
mixture was stirred for about 48 hr. A Kaiser test was performed to ensure coupling completion. The resin 
was filtered and 2 ml of the solution was poured into a micro-tube (For loading efficiency measurements 
by UV-Vis Spectrophotometer, SHIMADZU, Japan). The peptide-resin was suspended in cleavage cocktail 
(100 ml/mg of peptide-resin). The reaction vessel was shaken for two hours at room temperature. The resin 
was filtered and washed with a little additional freshly prepared cleavage cocktail. The combined filtrates 
in a three-neck glass flask were connected to Rotavapor-R to reduce the final volume to one-third of the 
initial volume under dry nitrogen flow. The combined filtrates in a three-neck glass flask were cooled to 4 
°C and cold diethyl ether (10 times more than the cleavage cocktail volume) was added to precipitate the 
yellow crude peptide. The peptides containing cleavage cocktail and Et2O were centrifuged at 4000 rpm for 
three minutes couple of times followed by decantation in order to obtain the solid peptide precipitate. 
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As a method which Cheng et al. introduced (28) and due to presumptions about ionization of some 
basic residues of synthesized peptides and MTX in a particular pH, the physical linkage between peptides 
and drug molecules was planned. The desired amount of peptide was weighed and dissolved in a little 
amount of DMSO. Acetic acid solution (0.1%) was added to attain the final volume about 1 ml. MTX was 
dissolved in 1 ml NaOH solution (10-4 M). Aforementioned solutions were mixed together and pH 
measurement was done carefully. Peptide-MTX conjugate was observed in Falcon tubes. 
 
Loading Methotrexate on Peptides and Drug loading efficiency calculations 
Herein, MTX loading efficiency was calculated indirectly. In other words, the amount of uncoupled 
MTX presence in the waste, which is gathered from the reaction vessel after MTX coupling procedure, can 
be measured spectrophotometrically. After completion of chemical/physical linkage between each peptide 
and MTX, the amount of drug loading was calculated by using U.V. spectroscopy (at λ=365 for chemical 
conjugation and at λ=306 for physical linkage). In physical linkage, the amount of drug was determined 
after centrifuge (4000 rpm, 10 min). For more accuracy, Amicon® Ultra-centrifugal filters were used in 
high speed ultra-centrifuge.  
 
Cell Culture 
MCF-7 is a human epithelial cell line derived from breast adenocarcinoma tissue, which is an adherent 
cell line. This cell line was obtained from Pasteur institute (Tehran, Iran). MCF-7 cells were grown in 
RPMI-1640 supplemented with 10% (v/v) fetal bovine serum and 100 U/ml penicillin, also 100 mg/ml 
streptomycin (hereafter referred to as complete medium) in a humidified atmosphere at 37 ºC with 5% CO2. 
The cells were split every 2–3 days to preserve the exponential growth. Routinely, in each subculture, the 
medium was removed and the cells were washed with sterile PBS buffer (pH 7.4), then a 0.25% trypsin-
EDTA solution (0.53 mM) was added. The cells were incubated at 37 °C for 5–10 minutes to detach them 
from the surface of the flask. Fresh medium was added to inactivate the trypsin and the cell suspension was 
centrifuged. The supernatant was discarded and the cells were resuspended in complete culture medium. 
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Additionally, the cells were counted using a hemocytometer and their viability was determined by the 
trypan blue dye exclusion method. Viability was always above 95%. Finally, the cells were split and 
dispensed to 25 cm2 or 75 cm2 culture flasks. 
 
Cell viability and Cytotoxicity Assay 
The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide], tetrazolium reduction 
assay, was the first homogeneous cell viability assay developed for 96-well plates. One day prior to the 
assay, the cells were seeded into 96-well plates at a density of 1.5×104 cells/well and incubated for ∼16 hr 
at 37 ºC with 5% CO2. Then, media was removed and different concentrations of peptides (25 µM, 50 µM) 
and peptide-MTX bio-conjugates (25 nM, 50 nM) were added to each well and plates were placed back in 
the incubator for an additional 24 hr, 48 hr and 72 hr. After definite times, peptide solutions were removed 
and each well was washed with PBS three times. Afterwards, 100 µl complete growth medium and 50 µl 
[3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide] (MTT; Roth) were added to each well 
(100+50=150 µl). The plates were incubated for 4 hr at 37 ºC. The unreacted dye was discarded and 200 ml 
DMSO and 25 µl Sorenson buffer (200+25=225 µl) were added to each well to dissolve the purple formazan 
crystals formed by the living cells. The cells without treatment were used as a control. The absorbance at 
570 nm of the solution in each well was read using a Microplate reader (TECAN, Austria). Cell viability 
was calculated relative to control wells according to the formula below:   
Cell viability = 
(𝐀−𝐁)
𝑨
×100% 
Where A was the absorbance of the control and B was the absorbance of the cells incubated with 
peptide and peptide-MTX bio-conjugates. Data was collected from at least 3 independent experiments 
performed in triplicates and analyzed by Graphpad prism software. 
 
Uptake studies: 
 Live Cell Imaging 
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MCF-7 cells were seeded in 6-well plates (5×105 cells/well) and cultured for ∼20 hr in serum-
containing RPMI-1640 and incubated at 37 ºC with 5% CO2. The next day, stock solutions (100 μM) of 
FAM-labeled CPPs and their nano-complexes in antibiotic-free culture medium were diluted in medium to 
final concentrations (25 μM and 50 μM). The culture medium was removed and the peptide solutions were 
added to each well. After 1.5 hr incubation at 37 °C, the cells were washed three times with PBS buffer. 
Afterwards, the samples were stored protected from light at 4 °C until the plates were placed in a live cell 
imager apparatus and observed by Cytation 5 (Biotek, USA) under bright field and FITC channels. 
 
 Confocal Microscopy 
MCF-7 cells were seeded on coverslips in a 6-well plate (5×105 cells per well) and cultured for ∼22 
hr in serum-containing RPMI-1640 and incubated at 37 ºC with 5% CO2. The next day the stock solutions 
(100 μM) of the test compounds were diluted in antibiotic-free medium to a final concentration of 50 μM. 
The medium was removed from the plate and the peptide solutions were added to each well. The cells were 
incubated for 2 hr at 37 °C before the peptide solutions were removed. The cells were washed three times 
with PBS buffer and fixed with 4% paraformaldehyde for 20 min. at room temperature. Afterwards, the 
cells were washed twice with PBS buffer and treated with RNase (DNase free) enzyme to cleave probably 
double strand molecules except DNA. Propidium iodide (0.4 mg ml−1 stock solution in PBS buffer) was 
added to each sample for 5 min. at room temperature to stain the dead cells (final concentration 0.02 mg.ml
−1). The cells were washed twice with PBS and the coverslips were placed cell-side-down on cytoslides with 
4 μL mounting medium. After drying, coverslips were fixed with colorless nail polish. Samples were stored 
protected from light at 4 °C until measurements using a confocal laser scanning microscope (TCS-SP5 II, 
Leica, Wetzlar, Germany) equipped with a 20× and 63× objective lens were carried out. 
 
 Fluorescent Microscopy 
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MCF-7 cells were seeded on coverslips in 6-well plates (5×105 cells/well) and cultured for ∼18 hr in 
serum-containing RPMI-1640 and incubated at 37 ◦C with 5% CO2. The next day the stock solutions (100 
μM) of FAM-labeled CPPs and their nano-complexes in antibiotic-free culture medium were diluted in 
medium to final concentrations (25 μM and 50 μM). The culture medium was removed and the peptide 
solutions were added to each well. After 1.5 hr incubation at 37 °C, the cells were washed three times with 
PBS buffer and fixed with 3.7% formaldehyde for 10 min at room temperature Afterwards, the cells were 
washed with PBS buffer and samples were stored protected from light at 4 °C until the coverslips were 
placed cell-side-down on cytoslides and observed by an Olympus IX81 fluorescence microscope (Olympus 
Optical Co., Tokyo, Japan) under bright field and FITC channels (Excitation at 460-490/ Emission at 530 
nm). 
  
 Flow cytometry 
MCF-7 cells were seeded in 6-well plates (5×105 cells/well) and cultured for ∼20 hr in serum-
containing RPMI-1640 and incubated at 37 ◦C with 5% CO2. The next day, stock solutions (100 μM) of 
FAM-labeled CPPs and their nano-complexes in antibiotic-free culture medium were diluted in medium to 
final concentrations of 25 μM and 50 μM. The culture medium was removed and the cells were treated with 
peptide solutions. After 1.5 hr incubation at 37 °C, the cells were washed three times with PBS. The cells 
were digested with 0.25% trypsin-EDTA (0.53 mM) for 5 min to remove any artificial cell surface 
association and to detect only intracellular uptake. The cells were centrifuged at 3000 rpm (600 g) for 5 
min. and washed with PBS, then centrifuged two more times. The cells were resuspended in PBS, 
transferred to FACS tubes and were subjected to fluorescence analysis on a FACSCalibur Flow cytometer 
using an FL1 filter (Excitation at 488 nm and Emission at 515–545 nm). Live cells were gated by 
forwarding/side scattering (FSC and SSC) from a total of 10,000 events. 
 
Results 
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All Peptide sequences were synthesized manually by SPPS method on 2-Chlorotrityl chloride resin by 
Fmoc strategy. To ensure completeness of each coupling and deprotection cycle, Kaiser Test was 
performed. Peptide modification was applied using desired compounds and several types of peptides were 
cleaved from the resin, precipitated, lyophilized and stored in -20 ºC (all the synthesized peptides are listed 
in Table 1). 
Morphology of peptides before and after interaction with polyglutamate was analyzed by scanning 
electron microscopy. There were two peptide sequences; the first selected unmodified peptide sequence 
(COOH-QGRWKWKWK-NH2) with its nano-complex (COOH-QGRWKWKWK-NH2/E8) and on the other 
hand, the second selected modified peptide sequence (BA-QGRWKWKWK-pGlu) with its nano-complex 
(BA-QGRWKWKWK-pGlu/E8) were studied by SEM. Before adding E8, both unmodified and modified 
peptides had spherical shaped structures and sizes about 90 nm (Figure 1-A and Figure 1-C, respectively). 
However, the addition of E8 to unmodified peptide resulted in rod-shaped nanostructure and smaller sizes 
in comparison with peptide alone (Figure 1-B), the addition of E8 to modified peptides resulted in 
agglomerated and mixed sphere/rod-shaped nanostructures bigger than peptides alone (Figure 1-D). 
Zetasizer was used to measure the size of peptides as well as evaluate size distribution in peptides 
alone and their nano-complexes after interaction with polyglutamate. There were two peptide sequences; 
the first selected unmodified peptide sequence (COOH-QGRWKWKWK-NH2) with its nano-complex 
(COOH-QGRWKWKWK-NH2/E8) and on the other hand, the second selected modified peptide sequence (BA-
QGRWKWKWK-pGlu) with its nano-complex (BA-QGRWKWKWK-pGlu/E8) were assessed by ZS.  For 
peptide alone, 26.1%, 20.1% and 16.7% of the whole volume were for peptides with a diameter of 43.82 
nm, 37.84 nm and 50.75 nm, respectively (Figure 2-A). Interaction of COOH-QGRWKWKWK-NH2 with E8 
resulted in a smaller size but the average size is bigger than peptide alone. For example, 25.5% of particles 
were in a size 32.67 nm. 20.5% and 16% of the whole volume were for particles with a size of 28.21 nm 
and 37.84 nm, respectively (Figure 2-B). For modified peptide alone (Figure 2-C), 36.5% and 34.5% of 
the whole volume were for peptides with a diameter of 24.36 nm and 28.21nm, respectively. Generally, the 
average size was 189.1 nm, which is smaller than the average size of unmodified peptide. Interaction of 
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BA-QGRWKWKWK-pGlu with E8 resulted in smaller average size than peptide alone, but size distribution 
range is inhomogeneous and sporadic (Figure 2-D). For example, 11.4%, 11.2% and 9.5% of particles were 
in a size 32.67 nm, 37.84 nm and 43.82 nm.  
However, zeta potential range for COOH-QGRWKWKWK-NH2 was between -17.8 mV to 34.4 mV and 
average zeta potential for this peptide was 11.9 mV (Figure 3-A), zeta potential range for BA-
QGRWKWKWK-pGlu was between 15.2 mV to 97.3 mV and average zeta potential for this peptide was 
33.7 mV (Figure 3-C). On the other hand, zeta potential range for COOH-QGRWKWKWK-NH2/E8 was 
between -7.68 mV to 18.4 mV and average zeta potential for this nano-complex was 6.30 mV (Figure 3-
B) and zeta potential range for BA-QGRWKWKWK-pGlu/E8 was between 69.3 mV to 144 mV, average zeta 
potential for this peptide was 27.5 mV (Figure 3-D).  
1H NMR spectra were recorded on a Bruker DRX-500 AVANCE at 500 MHz using TMS as internal 
standard and DMSO/D2O as solvent. For Mem-[WK]4-FAM sequence; Yield: 1H NMR-δ (500 MHz, d6-
DMSO/D2O, TMS): δ=10.78 (brs, 1H; Lys NH), 8.35 (brs, 1H; Trp ring H), 8.12-7.28 (m, 9H; FAM 
aromatic H), 4.7-4.5 (m, 1H; Trp Cα-H), 4.2 (brs, 1H; Lys Cα-H), 3.63-3.59 (m, 8H; Lys Cδ-H), 3.15-3.12 
(m, 8H; Trp Cβ-H), 1.62-1.55 (m, 8H; Lys Cβ-H), 1.27-1.24 (m, 8H; Lys Cγ-H), 1.2 (s, 1H; CH2-
Memantine), 0.9 (s, 6H; CH3-Memantine) (Figure 4-A). Also for BA-QGR-[WR]3-pGlu sequence Yield: 
1H NMR-δ (500 MHz, d6-DMSO/D2O, TMS): δ=10.69 (brs, 1H; Arg NH2), 8.22 (s, 1H; Trp ring H), 7.98-
7.97 (d, J=7.5 Hz, 1H; Trp ring H), 7.72-7.71 (d, J=8.5 Hz, 1H; Trp ring H), 7.45-7.35 (m, 3H; Trp ring H), 
7.27-7.1 (m, 5H; C-H Aromatic Benzyl), 4.35 (d, J=5.65 Hz, 2H; CH2-Benzylamine), 3.65-3.59 (m, 8H; 
Arg Cδ-H), 3.5-3.4 (m, 11H; Cα-H), 3.15-3.12 (m, 8H; Trp Cβ-H), 2.46 (t, 4H; CH2-
Glutamine/Pyroglutamate), 1.27-1.23 (m, 8H; Arg Cγ-H) (Figure 4-B). 
Cytotoxicity of unmodified CPPs, modified CPPs, modified CPP-MTX bio-conjugates and unmodified 
CPP-MTX bio-conjugates (both chemical conjugation and physical linkage) was evaluated in MCF-7 cells. 
The cells were treated with peptides and their bioconjugates in concentrations of 25 µM and 50 µM for 24 
hr, 48 hr and 72 hr. In Drug loaded CPPs, the cells were treated with peptides in concentrations of 25 nM 
and 50 nM, which were very lower than calculated IC50 concentration for free MTX in MCF-7 cells. Aiming 
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to consolidate this part of the research program, the peptides were divided into several groups. The first 
group was including; eight sequences with pyroglutamic acid (pGlu) at N-terminus and benzylamine (BA) 
at C-terminus as well as five sequences without modification. We have devised a strategy which was 
assessed the cytotoxicity of synthesized peptides without drug in separate subgroups in order to compare 
with each other. The first subgroup comprised of modified peptides with Benzylamine at C-terminus and 
Pyroglutamic acid at N-terminus in order to assess the safety of modified sequences. It is apparent from 
Figure 5-a that except BA-Poly K10-pGlu at concentration of 50 µM, any remarkable cytotoxicity was not 
seen, but treatment with the sequences BA-[WR]4-pGlu and BA-R8-pGlu  for 48 hr at concentration of 25 
µM showed increasing cell proliferation which is probably due to the stimulatory effect on the cell growth. 
The next subgroup of prepared peptides were five sequences without modification. After 48 hr incubation, 
the cells treated with this group of peptides showed viability changes but any remarkable toxicity was not 
observed (Figure 5-b). Considerable progress has been gained with regard to this group viability at a 
concentration of 25 µM, where the maximum cell viability was seen.  
The second group was including; five sequences physically linked to MTX and five sequences with 
chemical conjugated to the drug. Table 2 and Table 3 provide a short list of CPPs conjugated to MTX, 
CPPs with physical linkage to MTX and their drug loading efficiency (%). To assess the cytotoxicity of the 
synthesized peptide-drug conjugates different subgroups were prepared and compared. The first subgroup 
comprised of modified peptides with Benzylamine (BA) at C-terminus and Pyroglutamic acid (pGlu) at N-
terminus, which were physically linked with MTX. These conjugate were produced based on the assembly 
of poly-cationic peptides in the presence of anionic MTX with two negative charges (Figure 6-a). The 
second subgroup comprised of unmodified peptides, physically linked to MTX as same as the first subgroup 
(Figure 6-b). The third subgroup was related to peptides without modification which was chemically 
conjugated to MTX (Figure 6-c). The cytotoxicity of free MTX was studied in the desired concentrations 
at 48 hr (IC50= 316.346 +/- 93.02 (29.4%) nM) (Figure 5-c). It is apparent from Figure 6-e that after 48 hr 
incubation, the viability was dramatically decreased except for WRWQGRWRW sequence but after 48 hr 
incubation, the viability was reduced in the case of modified peptides especially at the concentration of 50 
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µM. Among the five physically linked peptide-drug, BA-QGR-[WK]3-pGlu and BA-WRWQGRWRW-
pGlu displayed the highest cytotoxicity at 25 and 50 nM. The cytotoxicity of peptide-drug conjugates 
including QGR-[WK]3-MTX, WRWQGRWRW-MTX, [WR]4-MTX, [WR]3-QGR-MTX and QGR-
[WR]3-MTX was assessed and compared to that of free MTX. The obtained data revealed that among these 
sequences, QGR-[WK]3-MTX and WRWQGRWRW-MTX had toxicity, therefore cell viability was 
slightly reduced. Drug loaded CPPs at concentrations of 25 nM and 50 nM except for some sequences 
especially [WR]3-QGR-MTX exhibited anti-proliferative activity compared to the free MTX. Free MTX at 
a concentration of 50 nM showed 82% cell viability. The cell viability value was reduced to 67% and 64% 
with WRWQGRWRW-MTX and QGR-[WK]3-MTX at a concentration of 25 nM, respectively. 
The effects of N- and C-terminal modification on CPPs, besides their uptake and intracellular 
localization in MCF-7 cells, were evaluated by flow cytometry, fluorescent microscopy, live cell imaging 
and confocal microscopy. Cellular uptake studies for desired CPPs were designed in three different steps. 
In the first step, two sequences (poly R8 and poly K8) conjugated with 5(6)-FAM at N-terminus and their 
nano-complexes in concentrations of 25 µM and 50 µM were prepared (See Table 4). Our findings based 
on FACS flow cytometry would seem to show that polyarginine had higher uptake efficacy in comparison 
with polylysine. Our study has highlighted that adding E8 could not lead to dramatic change in uptake of 
polyarginine. Moreover, polylysine demonstrated higher internalization in comparison with polylysine 
nano-complex in both concentrations (25 µM and 50 µM). As shown in Figure 7-A there was not any 
remarkable difference between Poly R8-FAM and its nano-complex in the case of cell internalization. In 
comparison with unstained samples, FAM-labeled Poly R8 and its nano-complex had appropriate uptake. 
On the other hand, Poly K8-FAM and its nano-complex could not enter the cells efficiently. At the 
concentration of 25 µM, cellular uptake for FAM-labeled Poly K8 was higher in contrast with the 
concentration of 50 µM. Furthermore, FAM-labeled Poly K8/E8 nano-complex was demonstrated lower 
positive cells in comparison with peptide alone, therefore interaction between E8 and polylysine did not 
affect its uptake. 
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 In the second step, three sequences conjugated with 5(6)-FAM at N-terminus and Memantine at C-
terminus as well as their nano-complexes with concentrations of 25 µM and 50 µM were prepared (Table 
4). Our findings based on FACS flow cytometry data illustrated that internalization of these peptides was 
dramatically changed due to their modification on their N- and C-terminal in comparison with polyarginine 
and polylysine. In this step, FAM-labeled modified peptides including Mem-QGR-[WK]3-FAM, Mem-
QGR-[WR]3-FAM, Mem-WRWQGRWRW-FAM and their nano-complexes at concentrations of 25 µM 
and 50 µM were assessed. As shown in Figure 7-B, there was not any remarkable difference between Mem-
QGR-[WK]3-FAM and its nano-complex in cellular uptake. In comparison with unstained samples, FAM-
labeled modified peptides had cellular internalization, while in the case of Mem-QGR-[WR]3-FAM, Mem-
WRWQGRWRW-FAM and their nano-complexes, a determined decline was observed. Whereas 
internalization of the last peptide (Mem-WRWQGRWRW-FAM) was reduced to less than 60 %, uptake of 
this peptide was similar to its nano-complex. These modified peptides and their nano-complexes could not 
enter the cells efficiently in comparison with unmodified peptides. 
In the third step, to investigate the accuracy of previous data which were discussed before, it was 
decided to use a unique sequence. In this section, two similar sequences and their nano-complexes were 
used (Poly R8-FAM and Mem-Poly R8-FAM) (See Table 4). Either sequences were conjugated with 5(6)-
FAM at N-terminus, but one of them was end-capped with Memantine at C-terminus whereas the other one 
was unmodified. Polyarginine was chosen due to its great ability to penetrate the cell membrane. Figure 7-
C shows a significant difference in the cellular uptake of these two peptides in flow cytometry studies. As 
shown in Figure 7-C, unmodified polyarginine and its nano-complex in both concentrations had 
appropriate uptake. Except 25 µM concentration of modified peptide, other concentrations of this peptide 
exhibited low uptake in comparison with unmodified peptide and its nano-complex.  
Fluorescent images obtained by fluorescent microscopy (Figure 8), live cell imaging system (Figure 
9) and CLSM (Figure 10) showed that interaction between E8 and any desired peptides, caused a slight 
reduction in internalization of nano-complexes into the cells’ nucleus. The images of FAM-labeled peptides 
exhibit a dramatic reduction in cellular uptake with C-terminal modification. Although unmodified 
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polyarginine had the highest uptake at a concentration of 50 µM (Figure 8-B and Figure 10-B), its nano-
complex showed the highest uptake at 25 µM (Figure 9-E). Generally, Arginine containing peptides had 
better uptake than lysine or tryptophan-containing peptides. Arginine containing peptides were mostly 
distributed around the cells’ nucleus and it demonstrates homogeneous staining through cellular structures 
that were morphologically identified as the cell nucleus and nucleoli. Translocation of modified peptides 
was affected by their C-terminal modification and their uptake was dramatically decreased (Figure 8-F, 
Figure 8-H, Figure 9-H, Figure 9-K and Figure 10-H). Most of the modified peptides in fluorescent 
microscopy were distributed around the cell membrane (Figure 8-F, Figure 9-K and Figure 10-I). In 
conclusion, fluorescent microscopy data belong to all of the peptides and their conjugates demonstrate that 
the uptake of unmodified peptides especially octa-arginine is better than modified peptides. However, 
polyglutamate interaction with peptides probably decreases translocation of CPPs into the cell’s nucleus 
and intracellular delivery of these peptides could be influenced in the presence of E8.  
 
Discussion 
There is a major hurdle in the case of efficient passage through biological membranes for drug delivery to 
cancer cells. Without good translocation of drugs, high dose administration and side effects in different 
tissues, will be expected to that drug. Due to this, application of smart drug delivery systems like CPPs, is 
a reliable option for efficient drug delivery of suitable quantity of drug to the specific tissues. Altogether, 
more than 75 percent of published works on CPPs, are about Tat and pAntp, but in current study various 
sequences were designed and synthesized to fulfill intended goals (29). In this study, two main specific 
goals were in mind. The first one was a study about N-terminal and C-terminal modification of amphiphilic 
peptides and effects of these modifications on internalization/cytotoxicity of synthesized peptide sequences 
in comparison with unmodified peptides in-vitro. Another one was the study about loading efficiency of 
distinct strategies (i.e., Chemical conjugation vs. physical loading of MTX on peptide amphiphiles) besides 
toxic effects of both modified CPPs and peptide-MTX conjugates on the cells.  As a routine, the surface 
morphology, particle size, size/diameter distribution and average diameter of the synthesized peptides were 
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assessed by the SEM. Before adding E8, COOH-QGRWKWKWK-NH2 had spherical shaped structures and 
the size about 90-100 nm.  Polyglutamate addition, caused changes in the size and morphology of peptide. 
Actually, E8 addition to COOH-QGRWKWKWK-NH2, resulted in rod-shaped nanostructure, which is related 
to Polyglutamate negative charge culminating in electrostatic interactions with cationic peptides to form 
rod-shaped nanostructures and bigger average size in comparison with peptides alone. It was a key rule to 
analyze modified peptides morphology and compare them with its counterpart sequence without 
modification. The Modified peptide (i.e., BA-QGRWKWKWK-pGlu) had spherical shaped structures and the 
size of 90 nm before E8 addition, as same as unmodified peptide. Surprisingly, adding E8 to modified 
peptides (BA-QGRWKWKWK-pGlu/E8) resulted in agglomerated and mixed sphere/rod-shaped 
nanostructures bigger than peptide alone, also unmodified nano-complexes which were nearly 
unpredictable and unjustifiable in the presence of polyglutamate. The presumed reason responsible for this 
circumstance might be steric hindrance of modified peptides. Peptides formed rod-shaped structures in 
smaller sizes. SEM images and zetasizer analysis reported the size from 32.67 nm to 372 nm for unmodified 
peptide and its nano-complex, whereas sizes from 21.04 nm to 955.4 nm were observed in modified peptide 
and its nano-complex. The zeta potential of a nano-complex reflects the particles electrical potential and is 
influenced by the composition of the particle and the medium in which it is dispersed. Nano-complexes 
with a zeta potential above (+/-) 30 mV have been shown to be stable in suspension, as the surface charge 
prevents aggregation of the particles. In our study, zeta potential range for unmodified peptide and its nano-
complex were between -17.8 mV to 34.4 mV and -7.68 mV to 18.4 mV, respectively. On the other hand, 
zeta potential range for modified peptide and its nano-complex were 15.2 mV to 97.3 mV and 69.3 mV to 
144 mV, respectively. Our findings would seem to imply that modified peptides were more stable than 
unmodified peptides in suspension which prevent aggregation in standard condition due to the surface 
charge and steric hindrance. The results point to the likelihood that the average zeta potential is affected by 
adding polyglutamate (E8) to peptides. Polyglutamate addition decreases the average zeta potential in both 
unmodified and modified peptides. These results, justify agglomeration and mixed sphere/rod-shape of 
nanostructures in the presence of polyglutamate. Since last two decades, several versatile drug delivery 
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systems, including liposomes (30), block co-polymers (31), dendrimers (32), inorganic nanomaterials (33), 
proteins (34) as well as self-assembling small molecules (35) have been extensively studied and developed. 
Particularly, great interest has been focused on the self-assembling peptides as drug delivery vehicles, 
because of their good biocompatibility, flexible design, simple synthetic steps as well as facile modification 
and functionalization (36, 37). Generally, the self-assembled peptides’ nano-complexes can spontaneously 
form in aqueous solution or triggered by pH (38), ionic strength (39), enzyme (40, 41) or light (42, 43), 
temperature (44, 45), driving by non-covalent interactions, such as hydrophobic interaction, hydrogen 
bonding and π–π stacking (46). Nowadays, there are two main strategies in order to prepare drug-loaded 
nanomaterials based on self-assembling amphiphilic peptides (47). The first strategy is physically linkage 
(encapsulation) between drug and the self-assembled nanomaterials like peptides. For example, Stupp’s 
group has synthesized a self-assembled nanofiber of peptide amphiphile as the matrix to encapsulate 
camptothecin (an anticancer drug), which has shown good performance in in-vivo tumor growth inhibition 
(48). Ding’s group has also prepared self-assembled nanofibers of D-amino acid-based peptides to 
encapsulate 10-hydroxycamptothecin for drug delivery (49). The second strategy is the covalently linking 
the peptide with drug, affording peptide–drug bioconjugates (47). The peptide–drug bioconjugates are often 
able to self-assemble into nanostructures and possess higher drug loading efficiency as compared to the 
drug-encapsulated peptide nanomaterials. For instance, a taxol–peptide conjugate consisting of taxol, β-
sheet forming peptide and a cleavable linker was designed and synthesized by Cui’s et al., which could self-
assembled into supramolecular filaments with a drug loading content more than 41% (50). Moreover, both 
Xu’s (51) and Yang’s (36) groups have revealed that taxol conjugation with peptides has the ability of self-
assembling. The self-assembly capacity of peptides allows the taxol–peptide conjugates to form nano-
fibrous hydrogels, which serve as carriers and delivered components. Despite of these results, most of the 
peptide–drug conjugate required a peptide sequence with good self-assembly ability (52). In the current 
study, we used some amphiphilic peptides with the ability of self-assembly in order to Methotrexate 
delivery to the cancer cells. Methotrexate is one of the most effective and commonly used therapeutics in 
cancer chemotherapy. MTX entrance to the cells is handled by the RFC1 and once inside the cell, the 
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enzyme FPGS lead to polyglutamylation (53). Polyglutamylation of the drug, results in its retention within 
the cell, therefore binding to its target enzyme (i.e., DHFR) will increase dramatically. The effectiveness 
of MTX is often hampered by its hydrophilicity which results in poorly diffusion through cell membranes, 
also development of drug resistance mechanisms such as inhibition of active transport involving the cell 
folate receptor that mostly internalizes methotrexate. In order to bypass drug resistance and still retain 
cytotoxic activity, several strategies have been proposed. One of these strategies consists of chemical 
modification of methotrexate to improve lipophilicity of drug. Based on this strategy, in current research, 
chemical conjugation of MTX to amphiphilic cell penetrating peptides is responsible for uptake 
enhancement due to semi lipophilic characteristics of desired peptides, besides their especial ability to 
across biological barriers. On the other hand, due to the possibility of charge interaction between MTX and 
some positively charged residues of chosen peptides, we chose this drug in the second part of our study to 
compare with chemically conjugation of MTX with synthesized peptides. Nowadays, conjugation to CPPs 
is one of the most popular and efficient strategies to overcome extracellular barriers as well as for achieving 
intracellular delivery of cargos  (54). Lysosomal degradation of the chemotherapeutic drug is another major 
hurdle for successful cancer therapy. For nanocarriers to act efficiently, they must overcome these 
intracellular barriers such as endosomes and release the drugs into the cytosol before they are ultimately 
trafficked to lysosomes (55). Linking cargoes to peptides is an effective procedure to carry out some 
planned functions. Covalent coupling and non-covalent complex formation are two different methods used 
to link CPPs to cargoes. Covalent coupling is commonly used for conjugation of drugs, fluorescent labels, 
antibody fragments and targeting moieties to a peptide sequence (56). Non-covalent complexes are most 
widely used for delivery of oligonucleotides such as splice correcting oligonucleotides (SCO), siRNA and 
plasmids (57, 58). The main drawback of non-covalent interaction is its weak attraction which leads to 
uncontrolled release of cargo before reaching its target in some cases. In current study, both linking methods 
were used in order to compare different efficient drug delivery methods to targeted cells. Conjugation 
methods offer several advantages for in vivo applications including rationalization reproducibility of the 
procedure together with the control of the stoichiometry of the PTD cargo (3). MTX was negatively charged 
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(pH 7.4) (Methotrexate pKa 3.8, 4.8 and 5.6) (59) which caused an electrostatic attraction between MTX 
and the positively charged amino moiety of basic residues such as arginine (α-carboxylic acid (pKa1=2.01), 
α-amino (pka2=9.04) and side chain (pka3=12.48)) and lysine (α-carboxylic acid (pKa1=2.18), α-amino 
(pka2=8.95) and side chain (pka3=10.53)) in peptides. The hydrogen bonding might be present between the 
amino groups and -COO- groups in MTX molecules with the cationic amine (-NH2) of arginine or lysine in 
synthesized peptides at pH 6-6.5. Therefore large amount of the MTX molecules could be attached into the 
peptides by physical linkage due to ionization of desired moieties in MTX/peptides at specific pH value. 
Consequently, the higher the pH of the solution, the more negative charges are on the MTX, and the stronger 
attraction exists between the negatively charged MTX and the positively charged carriers, thus, the more 
difficult for loaded MTX to be released out of the carriers. The selection of these segments in carrier and 
MTX, as anticancer drug, was to achieve the larger drug loading and pH-dependent drug release. It is 
preferable that MTX releases at mild acidic pH with its release being prohibited considerably at 
physiological pH (7.4). In this way, the normal cells will be protected from toxic side effect of MTX and 
only the cancer cells will be targeted due to the effectiveness of pH-dependent physical linkages between 
MTX and peptide bioconjugates. Whichever the CPP considered, the common major concern is to avoid 
the endosomal pathway and/or to facilitate the escape of the cargoes from the early endosomes to prevent 
their degradation. One of the advantages of using CPPs for therapeutic and diagnostic delivery into the cells 
is the lack (or less) of toxicity in comparison with the other carriers, such as liposomes, polymers, etc. 
However, one of the problems using exogenous peptides for delivery of various molecules to mammalian 
cells is the ability to induce a humoral immune response against the therapy, which can be highly harmful 
for the subsequent treatments. Due to highly cationic nature of some CPPs, it may be proposed that they 
could be as toxic as other biopolymers. Therefore several groups evaluated different types of them in vitro 
and in vivo to ensure about their cellular toxicity. When the initial minimal membrane translocating Tat 
domain was discovered (60), any toxicity was not reported in very extreme conditions in HeLa cells (24 hr 
incubation at 100 micromolar concentration). Afterwards, in similar studies, this absence of toxicity was 
proved. For example, Toro et al. confirmed that the short Tat peptide was nontoxic for lymphocytes at dose 
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up to 300 μM (61). There was not toxicity for different cationic peptides (namely Tat, Antp, Rev and VP22) 
in Hela or Jurkat cells with up to 20–30 μM concentrations (62). Similar results were observed in a human 
trabecular meshwork cell line, primary human foreskin fibroblasts, Vero and HeLa cells. Zhang et al. 
reported that the C-terminal conjugated Tat peptide showed higher cellular uptake relative to the N-terminal 
analogue. They also showed that the doxorubicin conjugation to C-terminal partially overcame the multi-
drug resistance of cervical cancer cells, while the N-terminal conjugate showed no significant improvement 
in cytotoxicity when compared with free doxorubicin (63). We have obtained comprehensive results 
proving that, N- and C-terminal modification at least with mentioned process do not show any great changes 
in cytotoxicity of synthesized sequences. There is a strong probability that, peptide modification has no 
anymore toxic effects, therefore safety of these synthesize amphiphilic peptides has been approved. In the 
case of treatment with the sequences BA-[WR]4-pGlu and BA-R8-pGlu at 48 hr time table, concentration 
of 25 µM showed increase in cell proliferation which is probably due to the stimulatory effect on the cell 
growth. Consequently, in the case of MTX delivery to cancer cells, we believe strongly that toxic effects 
of MTX were increased in the presence of peptides compared to MTX alone. Within the framework of these 
criteria, considerable insight has been gained with regard to peptide use in drug delivery along with either 
chemical conjugation of drug to peptide and physical linkage between drug and peptide sequence. 
Obviously known, drug conjugation may has more loading efficiency, but physical entrapment will show 
more efficacy in an efficient drug delivery. 
For CPPs, it is widely accepted that the interaction of positively charged peptides (e.g., Polyarginine, 
etc.) with negatively charged cell membrane components like heparan sulfate and phospholipids is 
prerequisite for cell penetration (64). Generally, two major mechanisms including non-endocytotic 
mechanism and the endocytotic mechanism have been proposed depending on CPPs own features (e.g., 
cationic residues, concentration, etc.), the cargo molecule (size and physicochemical nature of cargo), the 
treated cell type and the membrane components (i.e., heparan sulfate and phospholipids) (65-67). Hirose et 
al. showed that conjugation of hydrophobic small molecules to arginine-rich CPPs resulted indirect 
translocation through the cell membrane at sites where the peptides formed unique “particle-like” structures 
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composed of multiple vesicles on the plasma membrane (68). In the absence of proteoglycans, Arginine 
uses other pathways to enter the cells (69). Studies also showed that Arginine-rich peptides with few 
residues could enter the cells sufficiently. So, this approves uptake for designed Poly R with eight residues 
(R8) in our study. The main mechanism for cellular uptake is not fully understood, but studies with 
fluorescent microscopy and flow cytometry support direct translocation of Arginine-rich peptides into the 
cells (70). It was found that the presence of tryptophan, increased the uptake of some CPPs like CADY, a 
highly efficient, synthetic and amphipathic tryptophan-rich peptide possessing the ability of cell membrane 
penetration via a non-endocytic pathway (71, 72). Octa-arginine (R8) is a sequence that we used to evaluate 
cell internalization efficacy in the presence of Memantine at C-terminus and 5(6)-FAM at N-terminus in 
comparison with no modification at C-terminus of the analogue peptide. Conjugating a hydrophobic peptide 
sequence FFLIPKG to either terminal of a homogeneous oligomer of arginine like R8, showed a significant 
effect on cell internalization ability of desired peptide (73). We investigate the effect of N-terminal and C-
terminal modification on internalization of CPPs to live cells with fluorescently labeled peptides utilizing 
fluorescence activated cells sorting (FACS) flow cytometry, Fluorescent microscopy, live cell imaging and 
confocal microscopy to quantify cellular uptake of the peptides. To study by fluorescent microscopy, the 
cells were fixed to reveal nuclear distribution of peptides, qualitatively. The problem with early studies in 
CPPs’ field was that, they predominantly relied on fluorescent microscopy of fixed cells or flow cytometry 
to measure uptake of CPPs. Two independent studies revealed that fixation of the cells could lead to 
artefactual redistribution of peptides, resulted in cell membrane-bounded CPPs (74, 75). Based on these 
studies, in spite of excess washing, cationic CPPs remained bound to the cell membrane, which interrupted 
findings about internalization in flow cytometry studies (4). However, flow cytometry could not distinguish 
between intercellular (i.e., membrane-bounded) and intracellular fluorescence, cell treatment and digestion 
with 0.25% trypsin/EDTA (0.53 mM) for 5 min was leaded to remove any artificial cell surface association 
and detect only intracellular uptake (76). On the other hand, unfixed cells were used to quantify cell 
internalization besides cytoplasmic distribution. Considering the presence of several positively charge basic 
residues in a peptide structure is a prerequisite. Therefore, different studies suggest the presence of at least 
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eight positive charges for an efficient internalization of cationic or amphiphilic CPPs (21). Due to this 
findings, we decided to use several positively charge basic residues as well as tryptophan in some sequences 
to better evaluation of interaction with cell membrane and internalization. To consolidate this step of our 
research, the internalization study was divided into three steps. Our findings would seem to show that 
polyarginine had higher uptake efficacy in comparison with polylysine. A guanidine head group in Arginine 
(R) can form hydrogen bonds with the negatively charged components of cell membrane including; sulfates 
and phosphates which leads to cell internalization under physiological pH-dependent conditions. Lysine 
(K) is a positively charged, basic amino acid similar to Arginine, but it does not have guanidine head group 
like arginine, therefore lysine is less effective than arginine in penetration to plasma membrane, 
individually. Peptides containing arginine and lysine interact with anionic/acidic components of the cell 
membrane in a receptor-independent manner (25-27, 77). Polycationic peptides like polylysine did not show 
efficient internalization as same as polyarginine in the study conducted by confocal microscopy (78). 
Studies have provided further evidence that polyglutamate (E8) addition to peptides resulted in improving 
cellular uptake (79, 80), however our study has highlighted that adding E8 could not lead to dramatic change 
in uptake of polyarginine. Moreover, polylysine demonstrated higher internalization in comparison with its 
nano-complex in both concentrations (25 µM and 50 µM). Our findings illustrated that internalization of 
N- and C-terminally modified tryptophan-containing peptides (see Table 4) was dramatically changed due 
to their modifications on both termini in comparison with aforementioned polyarginine and polylysine 
sequences. Even though the presence of tryptophan makes changes in uptake of some CPPs, herein end-
capping resulted in cellular uptake decrease. To investigate accuracy of previously discussed data, we 
decided to use a unique sequence (Herein; Poly R8) and its counterpart without C-terminal modification 
(see Table 4). We have demonstrated that some synthesized peptides in this research, strongly interacts 
with membrane lipids, mainly through its Trp-Arg-rich domains, that was shown to be critical for insertion 
of the peptide into the membrane. Mandal et al. showed the amphipathic nature of [WR]n (n=4, 5), also 
interactions of arginine and tryptophan residues with the corresponding negatively charged phospholipids 
and hydrophobic residues in the lipid bilayer may have played a role for initial entry into the cell membrane. 
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Hydrophobic interactions between tryptophan residues and the lipids result in possible distortion of the 
outer phospholipid monolayer, this leading to peptide internalization and enhanced cellular uptake of the 
cargo (81). Hence, a dramatic contradiction is seen here, which can be attributed to specific conformational 
change in second structure of synthesized peptides (α-helix and β-sheet). We have obtained comprehensive 
results proving that peptide N-terminal and C-terminal modification will result in reducing cell 
internalization, and direct site localization inside a cell near the nucleus as well. 
 
Conclusion 
In conclusion, the coupling of anticancer drug to CPPs provides a powerful tool in drug delivery with 
increased solubility, intracellular uptake and improved bio-distribution as well as pharmacokinetic profiles. 
We have obtained satisfactory results demonstrating that, the use of CPPs with a chemotherapeutic agent 
could lead to improved therapy. Some modified peptides interacted with MTX, including BA-QGR-[WK]3-
pGlu and BA-WRWQGRWRW-pGlu could successfully increase toxic effects of the drug in comparison 
with their unmodified counterparts. The cytotoxicity of modified peptides which were physically linked to 
MTX, considerably higher than both physically linked unmodified peptides and chemically conjugated 
peptides with MTX, whereas they had lower loading. Also, we have obtained comprehensive results 
proving that peptide end-capping will result in reduced internalization as well as direct site localization 
inside a cell. In contrary, increased drug toxic effects will be seen in the case of drug delivery using such 
these sequences. Uptake studies also approved the negative effects of our designed peptides in cell 
internalization, whether by increasing concentration or E8 addition. Finally, a number of potential shortfalls 
need to be considered. First, the present study has only investigated the effects of unmodified peptides as 
well as N-terminal and C-terminal modifications without peptide purification which can be responsible for 
some unpredictable errors. Second, this study has only investigated all these procedures in-vitro. 
Consequently, to obtain more accurate and reliable results, we recommend doing this research in-vivo. 
Also, peptide stability assessment procedures should be considered besides modification of CPPs. 
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FIGURE CAPTIONS 
Figure 1. Morphology analysis of peptides before and after interaction with polyglutamate by Scanning 
Electron Microscopy (SEM). Row (a): SEM Images of COOH-QGRWKWKWK-NH2 Peptide (A) and its nano-
complex (B), Row (b): SEM Images of BA-QGRWKWKWK-pGlu Peptide (C) and its nano-complex (D). 
 
Figure 2. Size distribution of peptides before and after interaction with polyglutamate by Zetasizer: (A) COOH-
QGRWKWKWK-NH2, (B) COOH-QGRWKWKWK-NH2/E8, (C) BA-QGRWKWKWK-pGlu and (D) BA-
QGRWKWKWK-pGlu/E8. 
 
Figure 3. Zeta (ζ) Potential of peptides before and after interaction with polyglutamate by Zeta analyzer: (A) 
COOH-QGRWKWKWK-NH2, (B) COOH-QGRWKWKWK-NH2/E8, (C) BA-QGRWKWKWK-pGlu and (D) BA-
QGRWKWKWK-pGlu/E8. 
 
Figure 4. 1H NMR (500.13 MHz) graph of (A): Mem-[WK]4-FAM and (B): BA-QGR-[WR]3-pGlu in DMSO/D2O 
to ensure that amidation was carried out. 
 
Figure 5. (a) Toxicity of modified peptides and (b) Toxicity of unmodified peptides to MCF-7 cells, (c) Drug 
concentrations to calculate IC50. The cells were incubated for 24 hr, 48 hr and 72 hr at 37 ºC with concentrations 
of 25 µM and 50 µM to cell viability assessment by MTT. (a) (P1: BA-[WR]4-pGlu, P2: BA-QGRWKWKWK-pGlu, 
P3:BA-QGRWRWRWR-pGlu, P4: BA-WRWRWRQGR-pGlu, P5: BA-WRWQGRWRW-pGlu, P6: BA-R8-pGlu, P7: BA-R10-pGlu, 
P8: BA-K10-pGlu), (b) (P1: C-WRWQGRWRW-N, P2: C-QGRWRWRWR-N, P3: C-QGRWKWKWK-N, P4: C-WRWRWRQGR-N, 
P5: C-[WR]4-N(. 
 
Figure 6. (a) Toxicity of unmodified peptides interacted with MTX (physical linkage) and (b) Toxicity of 
modified peptides interacted with MTX (physical linkage) to MCF-7 cells, (c) Toxicity of unmodified peptides 
conjugated with MTX. The cells were incubated for 24 hr, 48 hr and 72 hr at 37 ºC with concentrations of 25 
nM and 50 nM to cell viability assessment by MTT. (a) (BA-WRWQGRWRW-pGlu, BA-QGRWKWKWK-pGlu), (b) (C-
QGRWKWKWK-N, C-WRWRWRQGR-N, C-WRWQGRWRW-N), (c) (C-QGRWKWKWK-MTX, C-WRWQGRWRW-MTX, C-
[WR]4-MTX, C-WRWRWRQGR-MTX, C-QGRWRWRWWR-MTX). 
 
Figure 7. Cellular uptake of FAM-labeled peptides and peptide/E8 with concentrations of 25 µM and 50 µM in 
Live MCF-7 cells after 1.5 h incubation at 37 ºC. The uptake of peptides was studied by FACS Flowcytometer. 
(a) (P1: COOH-Poly R8-FAM, P2: COOH-Poly R8-FAM/E8, P3: COOH-Poly K8-FAM, P4: COOH-Poly K8-FAM/E8), (b) (P1: 
Mem-QGRWKWKWK-FAM, P2: Mem-QGRWKWKWK-FAM/E8, P3: Mem-QGRWRWRWR-FAM, P4: Mem- QGRWRWRWR-
FAM/E8, P5: Mem-WRWQGRWRW-FAM, P6: Mem-WRWQGRWRW-FAM/E8), (c) (P1: COOH-Poly R8-FAM, P2: COOH-Poly 
R8-FAM/E8, P3: Mem-Poly R8-FAM, P4: Mem-Poly R8-FAM/E8). 
Figure 8. (Fluorescent Images)- Row (a) Bright Field: A (R8-FAM 50 µM), C (R8-FAM 25 µM), E (Mem-R8-FAM/E8 50 
µM) and G (Mem-R8-FAM/E8 25 µM), Row (b) Fluorescent: B (R8-FAM 50 µM), D (R8-FAM 25 µM), F (Mem-R8-FAM/E8 50 
µM) and H (Mem-R8-FAM/E8 25 µM). 
 
Figure 9. (Live Cell Images)- Row (a) Bright Field (40x): A (R8-FAM 25 µM), D (R8-FAM/E8 25 µM), G (Mem-R8-FAM 
50 µM) and J (Mem-R8-FAM/E8 50 µM), Row (b) Fluorescent (40x): B (R8-FAM 25 µM), E (R8-FAM/E8 25 µM), H (Mem-R8-
FAM 50 µM) and K (Mem-R8-FAM/E8 50 µM), Row (c) Merged: C (R8-FAM 25 µM), F (R8-FAM/E8 25 µM), I (Mem-R8-FAM 
50 µM) and L (Mem-R8-FAM/E8 50 µM). 
 
Figure 10. (CLSM Images)   Row (a) Propidium Iodide (63x): A (R8-FAM 50 µM), D (R8-FAM 25 µM) and G (Mem-R8-
FAM/E8 50 µM), Row (b) Fluorescent (63x): B (R8-FAM 50 µM), E (R8-FAM 25 µM) and H (Mem-R8-FAM/E8 50 µM), Row 
(c) Merged: C (R8-FAM 50 µM), F (R8-FAM 25 µM) and I (Mem-R8-FAM/E8 50 µM). 
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Table 1.   Synthesized Peptide Sequences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Note: [MTX= Methotrexate Conjugated to N-terminal, FAM at N-Terminal=5(6) Carboxyfluorescein and Mem at 
C-Terminal=Memantine, BA at C-terminal= Benzylamine and pGlu at N-terminal=Pyroglutamic Acid] ** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C-Sequence-N Molecular weight (g/mol) 
COOH-WRWQGRWRW-NH2 1416.58 
COOH-QGR-[WR]3-NH2 1386.56 
COOH-QGR-[WK]3-NH2 1302.53 
COOH-[WR]3-QGR-NH2 1386.56 
COOH-[WR]4-NH2 1275.55 
COOH-Poly R8-FAM 1625.79 
COOH-Poly K8-FAM 1401.71 
Mem-Poly R8-FAM 1787.08 
Mem-QGRWKWKWK-FAM 1822.12 
Mem-WRWRWRQGR-FAM 1906.15 
Mem- WRWQGRWRW-FAM 1936.17 
BA-[WR]4-pGlu 1587.84 
BA-QGRWKWKWK-pGlu 1502.78 
BA-WRWRWRQGR-pGlu 1586.81 
BA-QGRWRWRWR-pGlu 1586.81 
BA-WRWQGRWRW-pGlu 1616.83 
BA-Poly R8-pGlu 1467.74 
BA-Poly R10-pGlu 1780.11 
BA-Poly K10-pGlu 1243.66 
COOH-[WR]4-MTX 1824.02 
COOH-QGRWKWKWK-MTX 1738.95 
COOH-WRWQGRWRW-MTX 1853.00 
COOH-WRWRWRQGR-MTX 1822.98 
COOH-QGRWRWRWR-MTX 1822.98 
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Table 2.   Loading Efficiency of Peptide-MTX Conjugates 
 
 
 
 
 
 
 
 
 
 
P1: COOH-QGRWKWKWK-NH, P2: COOH-WRWQGRWRW-NH, P3: COOH-[WR]4-NH, P4: COOH-
WRWRWRQGR-NH, P5: COOH-QGRWRWRWR-NH. (These unmodified peptide sequences were chemically 
conjugated with Methotrexate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Waste Abs. Wt.% drug (mg) in each Peptide-
MTX conjugate 
Drug Loading 
Efficiency (%) 
P1+MTX 0.40 8.76 36.0 
P2+MTX 0.36 23.6 95.6 
P3+MTX 0.28 21.73 88.0 
P4+MTX 0.37 17.90 72.5 
P5+MTX 0.30 18.08 73.0 
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Table 3.   Loading Efficiency of Peptide-MTX Physical Linkage 
 
 
 
 
 
 
 
 
 
P1: COOH-QGRWKWKWK-NH2, P2: COOH-WRWQGRWRW-NH2, P3: COOH-WRWRWRQGR-NH2, P4: BA-
QGRWKWKWK-pGlu, P5: BA-WRWQGRWRW-pGlu. (These unmodified peptide sequences were physically 
linked with Methotrexate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Waste Abs. Drug Loading Efficiency (%) 
P1+MTX   1.002 25.693 
P2+MTX 0.9665 23.834 
P3+MTX 1.0228 21.019 
P4+MTX 1.0568 32.576 
P5+MTX 1.067 54.818 
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Table 4.   Peptide Sequences used in Uptake studies 
 
 
 
 
 
 
 
 
 
 
** Note: [Mem at C-terminal=Memantine and FAM at N-terminal=5(6) Carboxyfluorescein] ** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Poly R8-FAM Mem-WRWQGRWRW-FAM/E8 
Poly R8-FAM/E8 Mem-[WR]3-QGR-FAM 
Poly K8-FAM Mem-[WR]3-QGR-FAM/E8 
Poly K8-FAM/E8 Poly R8-FAM 
Mem-QGR-[WK]3-FAM Poly R8-FAM/E8 
Mem-QGR-[WK]3-FAM/E8 Mem-Poly R8-FAM 
Mem-WRWQGRWRW-FAM Mem-Poly R8-FAM/E8 
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